Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

April 1-2, 2016

New York, New York

Scientific Agenda

Friday, April 1, 2016

8:00 am

Introduction and pre-activity audience survey

Session I: Plasma Cell Disorders

Session Chair: Robert Z. Orlowski, MD, PhD

8:10 am

Lecture: Monoclonal antibodies for multiple myeloma
Presenter: Ruben Niesvizky, MD

8:40 am

Debate: Standard induction for myeloma: RVD vs. KRD
KRD: Suzanne Lentzsch, MD, PhD
RVD: Paul G. Richardson, MD

9:10 am

Debate: High risk myeloma: Should it be treated differently?
Yes: Robert Z. Orlowski, MD
No: Speaker Invited

9:40 am

Break

9:55 am

Lecture: Cellular immunotherapies for multiple myeloma
Presenter: Edward A. Stadtmauer, MD

10:20 am

Challenging Cases in Multiple Myeloma Panel

11:05 am

Debate: Upfront transplant remains a standard of care
Yes: Edward A. Stadtmauer, MD
No: Suzanne Lentzsch, MD, PhD

11:35 pm

Debate: The best salvage therapy: RVD vs. KPD
RVD: Paul G. Richardson, MD
KPD: Robert Z. Orlowski, MD, PhD

12:05 pm

Final remarks and post-activity audience survey

12:15 pm

Lunch with the faculty

Session II: Chronic Lymphocytic Leukemia

Session Chair: David P. Steensma, MD

1:50 pm

Introduction and pre-activity audience survey

2:00 pm

Debate: Is CR and MRD negativity still required in the era of novel agents
Yes. The precedent for cure is by first attaining MRD negativity.
Matthew S. Davids, MD, MMSc
No. PR with ongoing response suggests that novel agent therapy is preferable. Presenter:
Richard R. Furman, MD

2:30 pm

Lecture: Clinical considerations for the use of oral targeted therapies in CLL
Presenter: Timothy Call, MD

2:55 pm

Debate: Optimal approach for the management of patients with del(17p)
Ibrutinib: Jacqueline Barrientos, MD
Novel agents: Paul Barr, MD
Allogeneic stem cell transplant in first remission: Edwin P. Alyea, MD

3:40 pm

Break

Session III: Chronic Myeloid Leukemia

Session Chair: David P. Steensma, MD

3:55 pm

Lecture: When can TKIs be stopped in CML
Jerald Radich, MD

4:20 pm

Lecture: CML molecular monitoring: practical advice
Jerry Radich, MD

4:45 pm

Lecture: Atypical CML: diagnosis and management
Eric Padron, MD

5:10 pm

Final remarks and post-activity audience survey

5:15 pm

Adjourn

Saturday, April 2, 2016

8:00 am

Welcome and pre-activity audience survey

Session IV: Not-So-Benign Hematology

Session Chair: David P. Steensma, MD

8:10 am

Lecture: Reversal of Newer Anticoagulants – when and how
Kenneth A. Bauer, MD

8:35 am

Lecture: Diagnosis and Management of Hemophagocytic Lymphohistiocytosis (HLH):
Sarah Nikiforow, MD, PhD

9:00 am

Lecture: Management of ITP
James B. Bussel, MD

Session V: Acute Leukemia

Session Chair: David P. Steensma, MD

9:25 am

Lecture: Addition of FLT3 inhibitors or other targeted agents to chemotherapy in AML
Richard M. Stone, MD

9:50 am

Break

Session VI: MPNs and MDS

Session Chair: David P. Steensma, MD

10:05 am

Lecture: Combination Therapy with JAK2 inhibitors in MPN
Ruben A. Mesa, MD

10:30 am

Lecture: Management of CMML
Eric Padron, MD

10:55 am

Hypomethylating agents are appropriate in lower-risk MDS
Yes:  Gail J. Roboz, MD
Only Use With Caution: Selina M. Luger, MD

11:25 am

Lecture: Promise and pitfalls in molecular testing in the diagnosis of MDS
Rafael Bejar, MD

11:50 am

Final remarks and post-activity audience survey

12:00 pm

Lunch

Session VII: Lymphomas

Session Chair: John P. Leonard, MD

1:30 pm

Welcome and pre-activity audience survey

1:35 pm

Debate:  What is the best approach for relapsed T cell lymphoma
Novel agents:  Steven M. Horwitz, MD
AlloSCT: Pier Luigi Porcu

2:05 pm

Debate: How should patients with ABC type DLBCL be treated today?
R-CHOP:  Richard I. Fisher. MD
R-EPOCH +/- novel agents: Peter Martin, MD

2:35 pm

Lecture: Immune checkpoint inhibitors in lymphoma
Anas Younes, MD

3:00 pm

Break

3:15 pm

Debate: Should young patients with mantle cell lymphoma be treated aggressively?
Yes: Brad S. Kahl MD
No: Jonathan Friedberg, MD

3:45 pm

Lecture: Update in primary CNS lymphoma management
Tracy Batchelor MD, MPH

4:10 pm

Debate: Should we do surveillance imaging for DLBCL patients in remission?
Yes: Mitchell R. Smith, MD, PhD
No: Morton Coleman, MD

4:40 pm

Lecture: What’s new in the initial management of Hodgkin Lymphoma?
Andrew M. Evens, DO, MSc

5:05 pm

Debate: Is watch and wait dead in follicular lymphoma?
Yes:  Michael E. Williams, MD, ScM
No :  John P. Leonard, MD

5:35 pm

Final remarks and post-activity audience survey

5:40 pm

Adjourn